today. during hope staying I times. Thank healthy for you, Phil. thank and safe is And and everyone you afternoon, unprecedented us these good everyone joining
headwinds during this As quarter. both to relating tailwinds experienced mentioned, and Phil while COVID-XX we
progress company’s the business units. We with are very pleased all in our of
X Phase of global injected our three call, last continued with met non-inferiority our primary children successfully daily somatrogon to growth trial dosed to months. evaluated its deficiency pivotal respect endpoint hormone in once-weekly velocity XX on after GENOTROPIN with discussed As height
for Meeting which presentation was the were and in June. oral Endocrine at in Two due COVID-XX Society’s March, rescheduled XXXX a Francisco abstracts virtual as San subsequently the dataset to as event a for accepted outbreak canceled
We the following or scheduled of are other of the present influence on Somatrogon, from administration like for Phase now results pivotal our both pertaining study one presentation and X to growth IGF-X factor data oral level an June Xth to abstracts, to
will Society, published addition, abstracts the or available in In issue Journal we in April, expect be a both be week supplemental which Endocrine online will so. the of May of
the is commercial half Pfizer the Our second XXXX. through application in partner biologics on submit of track FDA license the to
expect quarter March we application the XXXX submit XXXX. third was upon hormone treatment Europe, the mid-XXXX. demonstrating the open-label completion The compliance authorization to main for with in marketing is of completed to in Pfizer early of expected reduced which the In and are benefit a top-line still burden final study in and Japan complete data deficiency patients pediatric study in expected growth
with XXXX. to increase I quarter From our as follows: continued by XXXX down reported now for of would pharmaceutical a break IQVIA Turning commercial and a growth focus RAYALDEE commercial showed RAYALDEE, of compared the RAYALDEE. QX to as numbers X% performance on sequential increased with XX% like QX business, perspective, with Total the compared prescriptions
impacted in COVID-XX in unable XXXX physicians were Sales were to detail patient representatives declined our by of and doctor half sales negatively their offices. second March with visits offices the significantly as to
X,XXX decreased at starts QX and physicians. QX RAYALDEE by than versus in since X% patients XX,XXX patient New over prescribed launch, had less almost have
over X% XXX or new Approximately QX. were in of RAYALDEE prescribers prescribers of number the total physicians
to Fresenius launch commercial approval this anticipate Vifor and continues later first for year. partner European RAYALDEE Our
with our clinical indications. ongoing its making RAYALDEE to excellent are progress expand We to trial
and quarter, CKD vitamin X reported adult ongoing At regimens Phase D secondary comparing the for three from with insufficiency. end RAYALDEE common patients of an X clinical hyperparathyroidism the first interim X we stage trial results treatment with in or
to the the four dose CKD of results patients. micrograms effectively a RAYALDEE a XXX interim treatment to parathyroid indicate elevated per ml, is XXX required one that D of tested regimens nanograms of total in plasma serum daily raised The suppress hormone a that to the of reliably intact only of XX level range XX-hydroxyvitamin
Nearly now to the completed study are the of concerns safety and by the ongoing have of studies. data make results about has the second in the expected half of Final OPKO subjects sufficient XXXX. available to difficulties treatment of the between trial decided conclusions logistical and XX% are treatment there early. view end immense In posed pandemic,
exploring X formulation requiring We adult secondary also insufficiency. recently reported as new and trial clinical the and efficacy of treatment for in RAYALDEE interim for an regular hemodialysis Stage ongoing a high X Phase strained patients hyperparathyroidism safety from D of results a vitamin CKD
tolerated is metabolize by and to ongoing well of of the form data hyperparathyroidism. XXXX being is to kidney in the Interim quarter final first the results that indicate secondary of lack expected its function pandemic and with full is delayed the despite in treating RAYALDEE Enrollment successfully active expected half now capable XXXX. is top-line enrollment of second
pediatric to view safety RAYALDEE quarter XXXX third pandemic. start part study therefore OPKO of for has into if decided the completion patients a to post-marketing the to in must anyway continue We hemodialysis as in X planning risk their this in study clinic subjects as minimal a additional face and were possible, at regular to come all the of requirement. the with Phase
we after these ongoing order have exposure, extension to subsides the have the patients decided FDA. to complete unnecessary of initiation While the requested until from study pandemic we postpone an in to from time protect study
of X services, COVID-XX discusses wanted before on testing performed January and XX,XXX Labs I Jon now XXXX. during a Determination by for our the our the mention quickly tests as new were With BioReference and And Local place, Medicare began result reimbursement first this coverage quarter of Coverage we force year sales XKscore XKscore. Novitas. Medicare XKscore expansion nearly in resumed to of
was it COVID-XX into has following outbreak orders, second drop-off in which However, the continued the a significant in quarter. March,
we expect return be physician and resume However, visits at orders growth to to to offices. patients as lifted begin home stay to
force also our payers our plans to for will test. increase seek additional resume We the commercial sales and
the turn of Cohen to over a Lab discussion call Jon BioReference business. let that, for With Jon? me our
